Sign up Australia
Proactive Investors - Run By Investors For Investors

SeeThruEquity says Pressure BioSciences on pace to match 2015 guidance

SeeThruEquity CEO is pleased to see Pressure BioSciences exceed its top line guidance for the third quarter.
SeeThruEquity says Pressure BioSciences on pace to match 2015 guidance
The numbers add up for Pressure BioSciences.
SeeThruEquity reckons Pressure BioSciences (OTCQB:PBIO) looks on pace to match its 2015 annual estimate of $1.9mln in revenue, with growth in products and services augmented by a return of grant revenues.
 
The independent equity research firm issued an update on Pressure,  which provides technology for the preparation stage of lab testing in life science research, following recent results.
 
"We were pleased to see PBIO not only meet, but exceed its top line guidance for 3Q15," Ajay Tandon, chief executive of SeeThruEquity, said.
 
At the end of last quarter, management stated that the company should generate at least $500,000 in 3Q15 due to growing products and services revenue and in light of recent shipments and customer order activity, said SeeThruEquity.
 
Third-quarter top line results came in above $500,000, with revenues of $580,334 up 55.8% annually, a record for the company.
 
"This has been the trend for PBIO recently. At the beginning of the year, we noted that PBIO management guided for 2015 to be a watershed year for the company in which revenues would begin to achieve critical mass due to growth both from new products and services as well as grants.
 
Specifically, PBIO looks on pace to match our estimate of $1.9mln in revenue, with growth in products and services augmented by a return of grant revenues."
Based on the results and expectations for the near future, SeeThruEquity is maintaining its price target of $1.57 per share.
 
Shares of the South Easton, Massachusetts-based company rose 10.6% to $0.26 at 12:27 p.m. in New York.
View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
1527682514_angel-delight.jpg
May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use